Advertisement
Singapore markets close in 6 hours 13 minutes

  • Straits Times Index

    3,292.50
    +4.75 (+0.14%)
     

  • Nikkei

    37,776.46
    +147.98 (+0.39%)
     

  • Hang Seng

    17,517.93
    +233.39 (+1.35%)
     

  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     

  • Bitcoin USD

    64,427.45
    +202.64 (+0.32%)
     

  • CMC Crypto 200

    1,391.23
    +8.66 (+0.63%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,346.30
    +3.80 (+0.16%)
     

  • Crude Oil

    83.84
    +0.27 (+0.32%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • FTSE Bursa Malaysia

    1,572.19
    +2.94 (+0.19%)
     

  • Jakarta Composite Index

    7,117.80
    -37.49 (-0.52%)
     

  • PSE Index

    6,554.70
    -20.18 (-0.31%)
     

Mavyret May Prove a Strong Growth Driver for AbbVie Going Forward

Margaret Patrick
Updated
Mavyret May Prove a Strong Growth Driver for AbbVie Going Forward

In 3Q17, AbbVie (ABBV) reported global sales of nearly $276 million for its hepatitis C (or HCV) portfolio, which reflected a 27.7% operational fall and a 26.8% reported fall year-over-year (or YoY). The company reported HCV sales of close to $60 million from the US market in 3Q17, a YoY fall of ~19.5%. AbbVie also reported HCV sales of close to $216 million from international markets in 3Q17, a YoY fall of 29.8% on an operational basis and a fall of 28.7% on a reported basis.

Continue reading